Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Kedudukan dalam Saham #39173
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Harga Saham
$0.378
Disegerakkan terakhir: 2024-05-24
Modal Pasaran
$618.41K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan NeuBase Therapeutics, Inc. (NBSE)

Kategori

EPS untuk NeuBase Therapeutics, Inc. (NBSE)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham NeuBase Therapeutics, Inc., EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk NeuBase Therapeutics, Inc. dari 2026 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
Tidak cukup data untuk tarikh yang disediakan.
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE